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Abstract 
Traumatic brain injuries (TBIs) are a widespread public health concern affecting over 2.5 
million people in the United States alone (1).  TBIs are the leading cause of death and disability 
in children (ages 0-14), and their devastating effects can also be seen in vast population subsets 
such as professional athletes and combat soldiers (1).  
Damaged astrocytes, the specialized glial cells associated with the maintenance of the 
brain’s environment, respond to injury by altering regulation of certain proteins and ion channels 
in an attempt to maintain homeostasis (3).  Studies have also shown that following a TBI, 
astrocytes seek to regenerate, a phenomenon known as astrocyte reactivity. The purpose of this 
study was to develop a semi-interpenetrating network hydrogel to examine the expression 
astrocyte injury marker S100 calcium-binding protein B (S100B) and astrocyte reactivity marker 
glial fibrillary acidic protein (GFAP) following a mild TBI.  
To begin, I used a bioreactor designed by a previous student to simulate a compressive 
TBI.  Following this, I analyzed the expression of S100B and GFAP on the astrocyte cells using 
real-time PCR.  I also examined the effect of laminin on the astrocyte injury.  Multiple issues 
were encountered throughout the course of the project.  Challenges with cell culture and 
contamination were actively troubleshooted throughout the semester; however, despite the 
extensive investigations which are detailed in this paper, no clear solution was developed. 
The results of this project were inconclusive due to small sample size. Because S100B 
and GFAP are secreted following injury, our experiments suggest that the expression of these 
genes in the astrocytes were lower post-TBI. It also appears that laminin assists in protecting the 
astrocytes from extensive injury. In order to gain more accurate and conclusive results, the 
experiment sample size must be increased.   
Understanding the roles of these markers in relation to astrocyte injury is vital to the 
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1. Introduction  
Traumatic brain injuries (TBI) are a widespread public health issue affecting many 
populations in the United States, ravaging the lives of 2.5 million people annually (1). TBIs 
potentiate intracranial damage due to a large force to the head such as a blow or jerk. The 
immediate effects of a TBI include bleeding, swelling, memory loss, and headache (2).  TBIs are 
classified on a scale based on severity.  Mild TBIs are the most common and occur when one 
remains unconscious or disoriented for less than 30 minutes (12).  Common symptoms of mild 
TBIs (mTBIs) are fatigue, headache, irritability, memory loss, and sleep disturbances (12).  
Severe TBIs, in which loss of consciousness lasts longer than six hours, may also cause damage 
to brain tissue and long-term neurological disabilities resulting in limited functioning of the body 
(2).  
 Immediately following a TBI, the brain and its surrounding tissues undergo a series of 
major alterations, contributing to cell apoptosis and further neuron damage (3).  There are two 
stages to the pathophysiology of a TBI.  The primary damage from a TBI occurs directly at the 
moment of impact and includes such injuries as lacerations, bruising, and bleeding (6).  Perhaps 
the more worrisome and unpredictable damage occurs secondary.  This indirect damage occurs 
post-impact and includes edema, ischemia, and hypotension (6).  Mild TBIs can cause memory 
loss, headache, sleep disturbances, and irritability (12).  Moderate and severe TBIs can lead to 
hemorrhaging of the brain, memory loss, cell apoptosis, and even permanent paralysis.   
Following a TBI, the surrounding tissues of the brain undergo a series of major 
alterations in an attempt to maintain homeostasis within the central nervous system (4).  
Astrocytes and other cells that are involved in the maintenance of homeostasis within the brain’s 
environment alter gene expression after a TBI.  This alteration in the internal environment of 
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astrocytes contributes to the cell death and larger, more systemic damage of the brain and spinal 
cord. Two important genes that are involved in this process are S100 calcium-binding protein B 
(S100B) and glial fibrillary acidic protein (GFAP). Previous research has shown that S100B is 
expressed in response to cell damage in astrocytes; thus, it is traditionally used as a marker for 
cell injury (7).  Furthermore, S100B has been shown to be upregulated following astrocyte injury 
(7).  Additionally, studies have also shown that following a TBI, astrocytes seek to regenerate, a 
phenomenon known as astrocyte reactivity.  GFAP is used to characterize astrocyte reactivity 
after cell injury (8). GFAP is involved in the proliferation of astrocyte cells post-TBI, 
contributing to the formation of glial scars to facilitate the astrocytic healing process (8).   
 
1.1 Objectives: 
My main focus was to examine the expression of astrocytic GFAP and S100B following 
a simulated TBI.  The hypothesis of this study was that TBIs will lead to an increased expression 
of both S100B and GFAP in astrocyte cells.   Additionally, it was also hypothesized that the 
inclusion of laminin, a brain specific extracellular matrix protein, would confer possible 
protective effects on astrocyte cells.  To address this hypothesis, I subjected the astrocytes to a 
high-speed compression that mimics the strain experienced by the cells during a TBI by utilizing 
an in-house bioreactor designed by a previous research team member.  Following the TBI, gene 
expression was measured using quantitative real-time PCR.   
 
1.2. Significance of Research 
This research pertaining to traumatic brain injury will advance the understanding of 
S100B and GFAP expression after astrocyte injury.  By further characterizing the specific 
transformations that occur following a TBI, more effective treatments of TBIs and related 
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neurological injuries can be explored.  Furthermore, the experiences and techniques that I have 
gained from this research project have increased my critical thinking skills, problem-solving 
ability, and application of knowledge.  
 
1.3 Abbreviations and Definitions: 
 
BBB – blood-brain barrier 
 Semi-permeable membrane surrounding brain 
 Provides protection from substances and controls what enters the brain 
 
TBI – traumatic brain injury 
 Intracranial damage caused by jerk or blow to the head  
 
mTBI – mild traumatic brain injury 
 Unconsciousness or disorientation lasting less than 30 minutes 
 Most common type of TBI 
 
GFAP – glial fibrillary acidic protein     
 Provides support and strength for cells 
 Marker for astrocyte reactivity 
 
S100B – S100 calcium-binding protein B 
 Evaluates astrocytic damage  
 
Astrocyte or astrocyte cells 
 BBB-supporting cells 
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2. Literature Review 
2.1 Traumatic Brain Injury: 
TBIs are a major cause of death and disability in the United States (1).  Annually, of the 
2.5 million reported TBIs, 50,000 people died and 280,000 people were hospitalized (1). These 
numbers are most likely an underestimate, as they do not account for persons treated for TBIs 
both in US military hospitals and abroad. The CDC estimates that in 2010 alone, the economic 
costs associated with TBIs were $76.5 billion (1).  With this vast economic, social, and health 
burden, it is notable that most public health programs currently focus on the prevention of TBIs 
as the primary mechanism to control the issue.   
 The leading cause of TBIs are falls, accounting for almost half of reported TBIs (1).  The 
rates of TBIs are highest for persons aged 65 or older, and men are three times more at risk than 
women of suffering a TBI (1).      
 
Figure 1: Breakdown of leading causes of TBIs (1). 
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 Currently, the clinical treatments of TBIs lag behind the vast impact of the injury.  Once a 
TBI has occurred, little can be done to reverse the damage, and existing treatments focus on 
minimizing secondary damage (5). Patients may be given diuretics to control blood pressure, 
anti-convulsants to prevent seizures, and coma-inducting medications once they received 
medical care (5).  After damage assessment, patients may also participate in rehabilitation 
including speech, occupational, physical, and cognitive therapy programs (5).   
 Though the public health campaigns focusing on primary prevention have been effective, 
there is now a vital need for tertiary prevention to reduce the burden of TBIs and improve 
clinical outcomes.  Thus, it is currently important to focus research efforts on understanding the 
mechanisms behind the changes that surrounding brain tissues undergo directly following a TBI 
in order to develop new clinical treatment regimens.  
 
2.2 GFAP and Reactive Astrogliosis: 
 Glial fibrillary acidic protein (GFAP) is a protein which provides support and strength to 
cells (9).  Although not fully understood, GFAP is most likely involved in supporting astroglial 
cells through maintaining shape, support, and function (9).  Following such injuries as ischemia, 
trauma, and neurological conditions, astrocyte cells will respond with the development of new 
astrocytic cells, known as reactive astrogliosis (8).  Reactive astrocytes demonstrate altered gene 
expression and distinct morphological features.  In previous studies, GFAP has been shown to be 
upregulated during reactive astrogliosis and is considered a marker activated astrocytes (10). 
 Preliminary laboratory experiments have shown an increase in the proliferation of 
astrocytes 7 days post-TBI.  In order to further characterize this proliferation, we used GFAP as a 
marker of reactive astrogliosis.        
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2.3 S100B: 
 S100 calcium-binding protein B (S100B) is involved in the assessment of cell injury (8).  
It is expressed by mature astrocytes and is able to be isolated from serum in order to appraise the 
severity of brain damage (11).  Following a TBI, S100B gene expression should increase because 
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3. Materials and Methods  
 
3.1 Cell Culturing: 
Primary astrocytes isolated from the brain of neonatal rats were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) 10% fetal bovine serum (FBS) (including pen/strep and 
hepes) in T-75 flasks at 37°C and 5% CO2.  The cells were utilized once they reach 85% 
confluence in preliminary culture.  
 
Figure 2: Example of astrocytes during cell culture. 
For the TBI experiments, the cells were first suspended in a mixture of alginate, FBS, and 
3X DMEM. These cultured cells were then seeded onto a calcium chloride agar stamp to solidify 
overnight; the calcium chloride in the agar stamp allowed the gel to maintain a crystalline 
structure.  This creates a 3D model that could withstand the simulation of a TBI.  Laminin was 
also added to half of the cells to evaluate the effect of laminin on astrocyte injury.  Figure 3 








(-) Laminin (+) Laminin (-) Laminin (+) Laminin 
    




(-) Laminin (+) Laminin (-) Laminin (+) Laminin 
    
    
Figure 3: Demonstrates the 12-well plate arrangement. 
 Throughout the course of this project, our astrocyte cells became contaminated multiple 
times during cell culture.  In order to identify the source of the contamination, we performed the 
following tests (Figure 4): 
Suspected Source Actions  Outcome 
Media  Refiltered media 
 Utilized different medias on half 
of the cells 
Unsuccessful  
PBS  Refiltered PBS Unsuccessful  
Breakdown in aseptic 
technique  
 Replaced person responsible for 
cell culture  
Unsuccessful  
Incubator  Removed cells, sterilized 
incubator 
Unsuccessful  
Figure 4: Discusses actions taken to identify source of contamination during cell contamination 
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3.2 TBI Simulation:  
 24-hours after seeding the cells in suspension, I separated the gels from the agar stamp 
and added culture media.  One day later, I compressed the cells using a bioreactor (see Figure 5), 
simulating the force that the brain undergoes when a TBI occurs.  One day after compression, I 
isolated the RNA using the Qiagen RNeasy Isolation Kit, sequestering this for future gene 










Figure 5: Bioreactor device that was used to simulate a TBI.   
 
 We also experienced contamination of the gels.  In order to identify the source of the 
contamination, the following techniques were used (Figure 6):    
 
Suspected Source Actions Outcome  
Alginate    Sterilized alginate before use Successful  
Laminin  Refiltered laminin before use Unsuccessful  




3.3 Gene Expression: 
 After isolation of the mRNA, we utilized reverse transcriptase to convert the samples into 
cDNA.  This is more stable than mRNA, ensuring the integrity of the sample is maintained 
during storage.  Following this, real-time PCR was completed on the sample using the primers 
S100B and GFAP.  Each well was loaded with sterile water, SYBR Green, appropriate primer, 
and respective sample.  GAPDH was used as our control.  GAPDH is ubiquitous and is very 
stable throughout environmental strains such as compression.      
 




















Culture astrocytes in alginate/Laminin 
IPNs Traumatic Brain Injury Real-time PCR 















Development of a semi-interpenetrating network hydrogel to study the effects of mild traumatic 













4. Macro Perspective  
 
My examination of S100B and GFAP was a smaller aspect of Nasya Sturdivant’s, a PhD 
candidate of Dr. Kartik Balachandran, dissertation. The overall goal of her dissertation is to 
study how traumatic brain injury affects the brain and blood-brain barrier (BBB).  To develop 
new therapeutic interventions, it is necessary to further characterize the changes that occur post-
TBI.  As such, Nasya is investigating multiple proteins that may cause the secondary injury 
following a TBI.  I examined the specific genes S100B and GFAP which Nasya would like to 
include in her dissertation. 
Additionally, another main goal of Nasya’s thesis is to develop a new model for TBI 
simulation.  During a TBI, multiple events occur including stretch, compression, impact, 
collision, and jolt.  Because of the complexity of this event, simulating it accurately and 
holistically in the laboratory presents challenges.  To establish TBI simulations which resemble 
more realistic events, Nasya is also examining multiple models for TBI simulation by studying 
the impact of the type of force (ie stretch or compression) and environment (ie 3-D model or 2-D 







































5. Results and Discussion 
 Through real-time PCR, the genes S100B and GFAP were analyzed.  S100B is a gene 
used to examine cell injury (8).  Following a TBI, we expect astrocyte cells to exhibit more 
injury and thus more S100B than in the control.  Secondly, GFAP is a gene that is a marker for 
reactive astrogliosis (8).  After a TBI, astrocyte cells grow and proliferate rapidly to form a glial 
 
Examine effect TBI has on brain  
and blood-brain barrier 
 
 New model for TBI simulation 
  
 Environment  Force 
    
    3-D 2-D 
 
Compression  Stretch  
 
Figure 8: Provides a visual diagram of the macro-perspective on my honors thesis project. 
 S100B & GFAP 
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scar (10).  Because GFAP has been correlated with the formation of a glial scar, we expect 
GFAP to also increase following a TBI.       
 
 
Figure 9: Demonstrates the results of real-time PCR analysis for S100B and GFAP 
 
 Figure 9 displays the results of the real-time PCR analysis.  The y-axis displays the 
crossing point value at which the gene reaches a threshold during amplification.  The x-axis 
represents the control and TBI samples with and without laminin.  Following a TBI, S100B 
appears to increase the crossing point value, meaning that the amount of S100B in the cell 














































meaning that more amplifications cycles are required and thus less of the gene is present.  GFAP 
also has a larger crossing point value after a TBI, indicating that it too decreased in the astrocyte 
cells following a TBI.  The sample sizes and standard deviations for each are below: 
S100B 
Sample Sample Size Standard 
Deviation 
Control (+) Laminin 1 n/a 
Control (—) Laminin  2 0.70711 
TBI (+) Laminin  2 3.98808 
TBI (—) Laminin  2 1.94454 
 
GFAP 
Sample Sample Size Standard 
Deviation 
Control (+) Laminin 1 n/a 
Control (—) Laminin  2 1.43189 
TBI (+) Laminin  3 3.48031 
TBI (—) Laminin  1 n/a 
Figure 10: Describes sample size for each gene 
 GFAP and S100B are both genes that are also used as serum biomarkers following injury 
(8).  Because these are detectable in the bloodstream, astrocyte cells secrete them post-TBI.  This 
secretion following injury explains the lower values in the astrocyte TBI samples.  The astrocyte 
cells released these biomarkers into the extracellular environment after the injury, causing the 
lower detection inside the cells.  The laminin seems to have provided protective factors for the 
astrocyte cells as the samples with laminin expressed less injury and reactive astrogliosis.  
However, because of the low sample size, conclusions cannot be drawn based on this data.        
 22 
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6. Individual Skills Attainment 
 
6.1 Laboratory Skills: 
 Throughout this project, I gained a multitude of laboratory skills.  I have listed below the 
laboratory bench skills which I developed through my involvement in my honors thesis project 
and in the laboratory:     
 Cell culture  
 Primary cell isolation 
 RNA isolation  
 Real-time PCR 
 Project development 
  
6.2 Professional Development Skills 
In addition to laboratory bench skills, I gained experiences and developed skills which I 
will carry into the workplace.  Most importantly, my research provided me with a physiological 
perspective on disease.  This micro-biological perspective will enhance my future career by 
allowing me to grasp physiological disease progression and specific laboratory diagnostic 
methods.  Additionally, I learned through failed trials and project challenges that research 
requires methodical and persistent dedication to a task. I will carry this tenacity into my future in 
medical school and as a physician. Furthermore, because clinical treatments originate from 
various versions of the scientific method, I will be better prepared as a physician to be a humble 
lifelong learner who routinely and systematically seeks improvements in my work and in my 
methodology. 
 
6.3 Soft Skills 
During the semester, I also gained the soft skills listed below: 
 Problem solving 
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 Critical thinking 
 Information literacy through academic journal articles 
 Collaborative skills 
 Written communication skills 
 Oral communication skills 
 Data analysis  
 Creativity 
 Organization  
 
7. Conclusion and Future Work  
Because the sample size was low, no significant conclusions can be drawn from the 
results.  The sample size must be increased in order to see significant differences between the 
control and TBI astrocytes. 
In the future, we would like to increase the sample size to five for each respective sample.  
Additionally, three other markers for reactive astrogliosis will be examined in future studies 
including vimentin, IL-6, and TNF-alpha.  In order to sequester purer mRNA from each sample, 
it is important in future trials to maintain a sterile environment by wearing masks and lab coats to 
prevent any outside RNA contamination.  Additionally, strict use of RNAse Away is vital to 
maintain the integrity of the mRNA samples during handling.  Lastly, mRNA should be 
converted to cDNA directly after it is isolated and before it is frozen; this allows the sample to be 
more stable during storage.         
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A. Cell Culture 
 
Seeding Cells from Frozen Vials 
 
Reagents and Materials: 
 
Reagent Notes 
DMEM-10% FBS From pg. 1 of protocol 
(or other appropriate media type) 
Frozen vial of cells Retrieve from liquid N2 dewar 
Dulbecco’s phosphate buffered saline 
(dPBS) 
Invitrogen #14190250 
Cell culture plate Use T-25, T-75, T-175, P-60 etc as appropriate 
General rule of thumb: 50,000 cells per cm2 will 
yield confluent culture 
  
Coating cell culture plates:  
1% gelatin (if needed) Dissolve 1g gelatin (Sigma #G2500) in 100mL 
boiling water. Cool and sterile filter. 
1-50μg/mL fibronectin Dissolve 1mg fibronectin (BD Biosciences # 
354008) in 1mL cold sterile water (will yield: 
[FN] = 1mg/mL). Prepare 100μL aliquots and 




1. Prepare your substrates: 
a. Spray and transfer cell culture plate(s) into biosafety hood. 
b. Coat plates if your protocol calls for it. 
2. Warm up all reagents in the water bath (37°C). Warm frozen vial only to the point when the 
last sliver of frozen cells has melted. 
3. Spray down with EtOH and transfer to Biosafety Hood. 
4. Transfer contents of cell vial to 15mL/50mL conical tube and top up with at least 10 times 
the volume of media (eg: 10mL DMEM-10% FBS for 1mL frozen cells). 
5. Spin down in centrifuge at 4°C. A good starting point is 200xg for 5 min. 
6. In the meantime, aspirate cell culture coating and wash 3x with dPBS. 
7. Once cells have been centrifuged, return to biosafety hood and carefully aspirate media 
above the cell pellet. Take care that you don’t accidentally aspirate the cells! 
8. Gently resuspend the cells in appropriate volume of DMEM-10% FBS. Use about 5-10 
passes of the pipet to mix the cells evenly in the media. 
a. T-25: 2mL 
b. T-75: 10mL 
c. T-175: 25mL 
9. Remove 10μL of this solution for counting the number of cells. 
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10. Pipet cell solution to cell culture plate and gently tilt plate to ensure complete surface 
coverage of the cell solution. 
11. Label plate with: Your name/initials, date, cell type, passage number (will be found on frozen 
vial). 
12. Place cell culture plate in incubator at 37°C, 5% CO2.   
13. Allow cells at least 24 hours to attach to plate before feeding them. Feed cells every 2-3 days. 
 
 
Changing Media/Feeding Cells 
 
Reagents and Materials: 
 
Reagent Notes 
DMEM-10% FBS From pg. 1 of protocol 
(or other appropriate media type) 







1. Spray down microscope stage and examine cells. If cells look about 75-90% confluent, they 
need to be passaged.  
2. Warm up all reagents in the water bath (37°C).  
3. Spray down with EtOH and transfer to Biosafety Hood. 
4. Gently aspirate old cell culture media. Make sure you aspirate media from the edge of the 
flask. Tilt flask to facilitate media aspiration. 
5. Working quickly to prevent drying out of cells, wash cells 3x using dPBS. 
6. Gently tap flask against work surface of biosafety hood (if needed). 
7. After final wash, aspirate dPBS and add appropriate amount of DMEM-10% FBS. 
a. T-25: 2mL 
b. T-75: 10mL 
c. T-175: 25mL 
8. Place cell culture plate in incubator at 37°C, 5% CO2.   
9. Continue monitoring cells under microscope every day. 
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Sub-culture/Passaging of Cells 
 
Reagents and Materials: 
 
Reagent Notes 
DMEM-10% FBS From pg. 1 of protocol 
(or other appropriate media type) 
Dulbecco’s phosphate buffered saline 
(dPBS) 
Invitrogen #14190250 
(must not contain Ca2+ or Mg2+) 
Trypsin-EDTA Invitrogen #25300054 (0.05%) 
Invitrogen #25200056 (0.25%) 
Cell culture plate Use T-25, T-75, T-175, P-60 etc as appropriate 
General rule of thumb: 50,000 cells per cm2 will 




1. Determine the ratio of your passage/sub-culture. Typically one splits cells 1:2 or 1:3. 
2. Prepare required number of substrates as per pg. 2: 
3. Warm up all reagents in the water bath (37°C).  
4. Spray down with EtOH and transfer to Biosafety Hood. 
5. Gently aspirate old cell culture media. Make sure you aspirate media from the edge of the 
flask. Tilt flask to facilitate media aspiration. 
6. Working quickly to prevent drying out of cells, wash cells 3x using dPBS. This step is 
extremely important!!! 
7. Add appropriate volume of Trypsin-EDTA to disrupt cell-substrate and cell-cell binding. 
a. T-25: 0.5mL 
b. T-75: 1mL 
c. T-175: 2.5mL 
8. Return flask to incubator for 2min. After 2 min, check cells under microscope, they should 
have started to ball up and detach from the plate. Tap flask if necessary to dislodge the rest of 
the cells. 
9. Quench trypsin-EDTA reaction with 10-times the volume of DMEM-10% FBS. 
10. Using a pipet transfer contents to a 15mL/50mL conical tube. 
11. Spin down in centrifuge at 4°C. A good starting point is 200xg for 5 min. 
12. In the meantime, aspirate cell culture coating and wash 3x with dPBS. 
13. Once cells have been centrifuged, return to biosafety hood and carefully aspirate media 
above the cell pellet. Take care that you don’t accidentally aspirate the cells! 
14. Gently resuspend the cells in appropriate volume of DMEM-10% FBS. Use about 5-10 
passes of the pipet to mix the cells evenly in the media. 
15. Remove 10μL of this solution for counting the number of cells. 
16. Divide cell solution evenly to desired number of cell culture plates and gently tilt plate to 
ensure complete surface coverage of the cell solution. Top up with additional DMEM-10% 
FBS if needed. 
17. Label plates with: Your name/initials, date, cell type, passage number (make sure you 
increment the passage by 1). 
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18. Place cell culture plates in incubator at 37°C, 5% CO2.   
19. Allow cells at least 24 hours to attach to plate before feeding them.  
 
 
Culture Media Preparation 
 
Reagents and Materials: 
 
Reagent Notes 
DMEM Invitrogen #11995073 (contains L-glutamine) 
Fetal Bovine Serum (FBS) Invitrogen #10082-147 
(50mL aliquots; -20°C freezer) 
Pen-strep or antibiotic-antimicotic 
(100x) 
Invitrogen #15240-062 
(5mL aliquots; -20°C freezer) 
HEPES (1M) Invitrogen #15630080 
 
Other growth factors if required  This is typically based on your own modified 
protocol, experience, or the literature 
  




1. Warm up all reagents in the water bath (37°C). 
2. Spray down with EtOH and transfer to Biosafety Hood. 
3. Remove required amount of DMEM and dispose (eg: for DMEM-10% FBS remove 60mL). 
4. For DMEM-10% FBS add 50mL FBS, 5mL pen-strep, 5mL HEPES (i.e. bring the total 
volume back to 500mL) 
5. Swirl bottle to ensure proper mixing, and filter liquid using vacuum filtration unit. 
6. Immediately aliquot sterile, filtered DMEM-10% FBS into ten 50mL conical tubes. 
7. Label, initial, date tubes, and return to 4°C refrigerator. 
8. Use all aliquots within 2 weeks. 









Making 3D Alginate Gels for Mechanical Testing (Modulus, Swelling Characteristics, etc.) and 
SEM imaging. This protocol outlines the procedure to prepare 3D alginate gels at an alginate 
concentration of 0.1%, 0.5%, 1%, and 5% using 60mM and 100 mM CaCl2/agar stamps. The 





Alginic Acid Sodium Salt from brown 
algae (Alginate) 
Dissolve alginate in ddH20 to achieve the 
desired concentration. Vortex and set in water 
bath to aid dissolution. 
On Chemical Shelf 0.1%: 0.1g alginate in 100 mL ddH20 
 0.5%: 0.5g alginate in 100 mL ddH20 
 1.0%: 1g alginate in 100 mL ddH20 
 5.0%: 5g alginate in 100 mL ddH20 
5% Agar Solution 5g agar in 100 mL ddH20 
1 M CaCl2 Solution There is usually some already made in the 
4°C or on the chemical shelf, if not, the 
powder can be located on the chemical shelf. 




The amounts below make one 6 well plate of stamps (50 mL/plate) 
 
60 mM CaCl2/agar stamp solution 3 mL CaCl2 +  47 mL 5% agar solution 
100 mM CaCl2/agar stamp solution 5 mL CaCl2 + 45 mL 5% agar solution 
 
Make the stamp solution in a beaker, add a stir bar and loosely cover with foil. Boil the stamp 
solution on a hot plate at 90°C with the stir bar rotating. Where a protective glove and remove 
the solution from the hot plate and immediately begin pouring it into the wells of the 6-well 
plate. Fill each well up to about ¼ - 1/3 full. Let the plates cool to room temperature and then 
place in the 4C until you are ready to add the alginate. 
 
Pour 2-3 mL of 0.1%, 0.5%, 1% or 5% alginate solution on the CaCl2 stamps. Leave in the 37°C 
oven on the middle black table overnight. The alginate gels can now be removed from the 
CaCl2/agar stamps and used for viscoelastic property measurements using the rheometer. 
 
Prep for Swelling Tests and SEM 
Remove the alginate gels from the CaCl2/agar stamps and place in a petri dish. KEEP TRACK 
OF WHICH GEL IS WHICH. Prep the lyophilizer. Completely freeze samples with liquid N2. 
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Store samples in the -80°C until the lyophilizer is ready. Place samples in 50 mL conical tubes 
caped with a KEM wipe with tape wrapped around it. Leave in lyophilizer overnight. 
 
Swelling Tests: Cut the pieces so they have similar masses. Record each pieces dry weight. Add 
3 mL to each well of a 12 well plate. Put one piece in each well of a 12 well plate. Record the 
mass of each piece for 3 hours over a 12 hour period. 
 





From the mechanical testing we discovered that when 0.5% alginate is crosslinked with 60 mM 
CaCl2/agar stamps it creates a hydrogel with a storage modulus close to that of the brain. For this 
reason, the cell viability staining, osmolality tests, and protein expression will be done on 
astrocytes encapsulated in 0.5% alginate crosslinked with 60 mM CaCl2/agar stamps. 
 
Alginate Prep  
1. Prepare 1.765% (for 1%) alginate in sterile deionized water. 
2. Adjust pH of alginate to 7.4 using NaOH (basic) and HCl (acidic). 
3. Filter the alginate in the cell culture hood. Place in 4°C until ready for use.  
 
3D Cultures of Cells in Alginate Gels 
 
1. Calculate the total volume of alginate solution needed: 
3mL/chamber 
 
2. Trypsinize cells. Count. Remove needed amount of cells (500,000 cells/chamber) and 
spin down. Re-plate the remainder cells.   
Reagent Notes 
DMEM (3X concentrated) Sigma #D7777 
(Reconstitute the powder (Entire “1L” bottle)  
in 333mL ddH2O + 3.7g Sodium Bicarbonate; 
Filter sterilize; Aliquot to 15mL tubes and 
freeze in -20°C) 
3Volume Total  Volume   
DMEM Volume = Total Volume ÷ 3 
(Use the 5mL filtered aliquots in -20°C) 
Fetal Bovine Serum (FBS) Invitrogen #10082-147 (50mL aliquots; -20°C 
freezer) 
FBS Volume = Total Volume × 0.1 
(To make the solution 10% FBS) 
0.8825% Sterile Alginate Alginate Volume = T.Volume – DMEM – 
FBS 
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3. Resuspend cells in the appropriate amount of 3X DMEM. Then, add in FBS and 
Alginate. 
4. Mix the solution well but take care to avoid the generation of bubbles. 
5. Immediately transfer 3mL of the cell suspension into each well of the 6-well plate with 
the CaCl2/agar stamps. 
6. Allow the solution to gel overnight at 37°C, 5% CO2, 100% humidity (i.e. in the 
incubator) 
7. Feed the gel with 2 mL normal DMEM-10% FBS 
 
Note: To make a gel with an alginate concentration other than 1%, multiply the desired alginate 
concentration by 1.765. Example: For a 5% alginate gel, multiply 1.765 by 5. You will now 
create your alginate solution with a 8.825% alginate, yielding a gel with a final alginate 



































C. Purification of Total RNA from Rat Astrocyte Cells 
Checklist 
 Spray countertop, pipetters, pipet boxes, 2 microcentrifuge tube holders, etc. down with 
DNase/RNase Away. 
 Grab the Buffer RW1. 
 Prep Buffer RLT Plus. Make sure β-mercaptoethanol (β-ME) was added to Buffer RLT 
(check on the bottle top). If not, Add 10 uL β-ME per 1 mL Buffer RLT Plus. Buffer 
RLT Plus is stable at room temperature for 1 month after the addition of β-ME 
o Buffer RLT Plus may form a precipitate during storage. If necessary, redissolve 
by warming, and then place at room temperature. 
 Prep Buffer RPE working solution. Make sure ethanol has been added to Buffer RPE 
to create the working solution (check on the bottle top). If not, add 4 volumes of ethanol 
(96-100%), as indicated on the bottle. 
 Prep 70% ethanol. 1400 µL per 1.5mL microcentrifuge tube. 980 µL ethyl alcohol + 
420 µL sterile water.  
 Perform all steps of procedure at room temperature and work quickly. 
 Perform all centrifugation steps at 20-25°C 
 Label QIAshredder spin column placed in 2 mL collection tube (purple columns) 
 Label and cap gDNA Eliminator spin column placed in a 2 mL collection tube (clear 
columns) 
 Label RNeasy spin column placed in a 2 mL collection tube (pink columns) 
 Grab empty 2 mL collection tubes for step 24 
 Label clear 1.5 mL microcentrifuge tubes for the final RNA sample 
Protocol 
1. In the cell culture hood, label 15 mL centrifuge tubes with the name of your samples. 
2. Remove alginate gels from the incubator and place in the hood. 
3. Add 1 mL of 100mM EDTA to each gel. 
4. Allow the gels to dissociate in the CaCl2. Pipetting of the gel/CaCl2 solution may be 
necessary to break up the gel. Pipet the gel/CaCl2 solution into the respective 15 mL 
centrifuge tube. Do this for all the gels, changing the pipet tip between each sample. 
5. Centrifuge the gel/CaCl2 solution at 500 G for 2 mins.  
6. Remove the supernatant being careful not to disrupt the cell pellet. Add 1 mL of sterile 
1X PBS to the cell pellet, wash the cells by mixing, then centrifuge at 500 G for 2 mins. 
7. Repeat step 6. 
8. Bring the centrifuge tubes containing just the cell pellets to the PCR counter. Spray down 
with DNase/RNase Away. 
9. Disrupt the cells by adding 350 µL of Buffer RLT Plus to each cell pellet. 
10. Pipet each pellet to mix and pipet the lysate directly into its respective QIAshredder spin 
column. 
11. Centrifuge for 2 min at maximum speed. 
12. Transfer the homogenized lysate to the respective gDNA Eliminator spin column. 
13. Centrifuge for 30 sec at max speed. 
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14. Discard the column, and save the flow-through. 
15. Add 350 µL of 70% ethanol to the flow through, and mix well by pipetting. 
16. Transfer the 700 µL of the sample, to the respective RNeasy spin column. Close the lid 
gently. 
17. Centrifuge for 15 sec at max speed. Discard the flow-through and reattach the column to 
the collection tube. 
18. Add 700 µL Buffer RW1 to the RNeasy spin column. Close the lid gently. 
19. Centrifuge for 15 sec at max speed to wash the spin column membrane. Discard the flow-
through and reattach the column to the collection tube. 
20. Add 500 µL Buffer RPE to the RNeasy spin column. Close the lid gently. 
21. Centrifuge for 15 sec at max speed to wash the spin column membrane. Discard the flow-
through and reattach the column to the collection tube. 
22. Add 500 µL Buffer RPE to the RNeasy spin column. Close the lid gently. 
23. Centrifuge for 2 mins at max speed to wash the spin column membrane. 
24. Place each RNeasy spin column in new 2 mL collection tubes and discard the old 
collection tubes with the flow through.  
25. Centrifuge at max speed for 1 min. 
26. Place the RNeasy spin column in the final labeled 1.5 mL centrifuge tube. 
27. Add 30-50 µL of sterial RNase-free water directly to the spin column membrane. Close 
the lid gently. 
28. Centrifuge at max speed for 1 min to elute the RNA. 
29. Trash the columns and place samples in a box in the -80°C. 
 
 
 
